Zacks Research Comments on Halozyme Therapeutics, Inc.’s FY2026 Earnings (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Investment analysts at Zacks Research lifted their FY2026 earnings per share estimates for Halozyme Therapeutics in a research report issued to clients and investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of $5.16 per share for the year, up from their previous forecast of $5.08. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.45 per share.

A number of other analysts have also issued reports on HALO. TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. The Goldman Sachs Group decreased their price objective on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a research note on Thursday, January 18th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, April 17th. JMP Securities reiterated a “market outperform” rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. Finally, Benchmark reiterated a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $53.29.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $38.97 on Wednesday. The firm has a market cap of $4.95 billion, a PE ratio of 18.47, a PEG ratio of 0.45 and a beta of 1.25. The stock’s fifty day moving average price is $39.62 and its two-hundred day moving average price is $37.78. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50. Halozyme Therapeutics has a 1 year low of $29.85 and a 1 year high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $230.04 million during the quarter, compared to the consensus estimate of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the transaction, the senior vice president now directly owns 156,558 shares in the company, valued at $6,519,075.12. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders sold a total of 30,000 shares of company stock worth $1,196,800 over the last ninety days. 2.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vontobel Holding Ltd. purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter worth about $249,000. Exchange Traded Concepts LLC boosted its holdings in shares of Halozyme Therapeutics by 16.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 14,129 shares of the biopharmaceutical company’s stock worth $540,000 after purchasing an additional 1,974 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in shares of Halozyme Therapeutics by 8.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 23,869 shares of the biopharmaceutical company’s stock valued at $912,000 after acquiring an additional 1,800 shares during the last quarter. Linden Thomas Advisory Services LLC lifted its stake in shares of Halozyme Therapeutics by 13.7% in the 3rd quarter. Linden Thomas Advisory Services LLC now owns 42,450 shares of the biopharmaceutical company’s stock valued at $1,622,000 after acquiring an additional 5,126 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its stake in shares of Halozyme Therapeutics by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 16,216 shares of the biopharmaceutical company’s stock valued at $619,000 after acquiring an additional 347 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.